Psilocybin Fragile X Syndrome Treatment VANCOUVER, BC, Nov. 2, 2021 /CNW/ – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders, is pleased to announce that the U.S. FDA has approved the Company’s…


Previous articleCybin Hosting Research and Development Briefing on November 8, 2021
Next articleMydecine Files Full Patent Application Covering New Formulations that Bring Nanoemulsion Technology to Traditional Medicine Ingredients